| Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness ZY Zheng, H Elsarraj, JT Lei, Y Hong, M Anurag, L Feng, H Kennedy, ... Breast Cancer Research 24 (1), 68, 2022 | 590 | 2022 |
| Integrated proteogenomic characterization of clear cell renal cell carcinoma DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ... Cell 179 (4), 964-983. e31, 2019 | 467 | 2019 |
| Proteogenomic characterization of endometrial carcinoma Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ... Cell 180 (4), 729-748. e26, 2020 | 336 | 2020 |
| Proteogenomic landscape of breast cancer tumorigenesis and targeted therapy K Krug, EJ Jaehnig, S Satpathy, L Blumenberg, A Karpova, M Anurag, ... Cell 183 (5), 1436-1456. e31, 2020 | 327 | 2020 |
| Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma C Huang, L Chen, SR Savage, RV Eguez, Y Dou, Y Li, ... Cancer cell 39 (3), 361-379. e16, 2021 | 224 | 2021 |
| A proteogenomic portrait of lung squamous cell carcinoma S Satpathy, K Krug, PMJ Beltran, SR Savage, F Petralia, C Kumar-Sinha, ... Cell 184 (16), 4348-4371. e40, 2021 | 203 | 2021 |
| The prognostic effects of somatic mutations in ER-positive breast cancer OL Griffith, NC Spies, M Anurag, M Griffith, J Luo, D Tu, B Yeo, J Kunisaki, ... Nature communications 9 (1), 3476, 2018 | 126 | 2018 |
| Microscaled proteogenomic methods for precision oncology S Satpathy, EJ Jaehnig, K Krug, BJ Kim, AB Saltzman, DW Chan, ... Nature communications 11 (1), 532, 2020 | 99 | 2020 |
| Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer JT Lei, J Shao, J Zhang, M Iglesia, DW Chan, J Cao, M Anurag, P Singh, ... Cell reports 24 (6), 1434-1444. e7, 2018 | 99 | 2018 |
| Endocrine therapy resistance: new insights JT Lei, M Anurag, S Haricharan, X Gou, MJ Ellis The Breast 48, S26-S30, 2019 | 95 | 2019 |
| Comprehensive profiling of DNA repair defects in breast cancer identifies a novel class of endocrine therapy resistance drivers M Anurag, N Punturi, J Hoog, MN Bainbridge, MJ Ellis, S Haricharan Clinical Cancer Research 24 (19), 4887-4899, 2018 | 79 | 2018 |
| Loss of MutL Disrupts Chk2-dependent Cell Cycle Control Through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer Cancer Discovery, 2017 | 76 | 2017 |
| Neurofibromin is an estrogen receptor-α transcriptional co-repressor in breast cancer ZY Zheng, M Anurag, JT Lei, J Cao, P Singh, J Peng, H Kennedy, ... Cancer cell 37 (3), 387-402. e7, 2020 | 70 | 2020 |
| Immune checkpoint profiles in luminal B breast cancer (Alliance) M Anurag, M Zhu, C Huang, S Vasaikar, J Wang, J Hoog, S Burugu, ... JNCI: Journal of the National Cancer Institute 112 (7), 737-746, 2020 | 68 | 2020 |
| Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness Y Li, TSM Lih, SM Dhanasekaran, R Mannan, L Chen, M Cieslik, Y Wu, ... Cancer Cell 41 (1), 139-163. e17, 2023 | 63 | 2023 |
| Integrated proteogenomic characterization of clear cell renal cell carcinoma DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ... Cell 180 (1), 207, 2020 | 53 | 2020 |
| Crowd Sourcing a New Paradigm for Interactome Driven Drug Target Identification in Mycobacterium tuberculosis R Vashisht, AK Mondal, A Jain, A Shah, P Vishnoi, P Priyadarshini, ... PloS one 7 (7), e39808, 2012 | 48 | 2012 |
| Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort AS Cheng, SCY Leung, D Gao, S Burugu, M Anurag, MJ Ellis, TO Nielsen Breast cancer research and treatment 179, 3-10, 2020 | 46 | 2020 |
| DNA damage repair defects as a new class of endocrine treatment resistance driver M Anurag, MJ Ellis, S Haricharan Oncotarget 9 (91), 36252, 2018 | 42 | 2018 |
| Unraveling the potential of intrinsically disordered proteins as drug targets: application to Mycobacterium tuberculosis M Anurag, D Dash Molecular BioSystems 5 (12), 1752-1757, 2009 | 38 | 2009 |
Matthew J. EllisPhysician Scientist, Oncologist在 progendis.com 的电子邮件经过验证
